KRIYA-825 / Kriya Therap - LARVOL DELTA

Everads Announces Five Abstracts Accepted for Presentation at ARVO 2025, Including First-in-Human Results Using its Novel Suprachoroidal Injector (PRNewswire) - "Everads Therapy...today announced that five abstracts — including first-in-human data — have been accepted for presentation at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, taking place next week in Salt Lake City, Utah...The company's first-in-human study (NCT06314217) is an open-label safety and performance trial evaluating the Everads Injector for suprachoroidal administration of a triamcinolone acetonide suspension in patients with diabetic macular edema (DME). Clinical results demonstrate the safety, feasibility, and ease of use of the Everads Injector in an office-based setting."

Clinical data • Preclinical • Diabetic Macular Edema • Ophthalmology

Kriya Announces Thirteen Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2025 (GlobeNewswire) - "Kriya Therapeutics, Inc...announced thirteen presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will be held May 13 to 17, 2025 in New Orleans, LA."

PK/PD data • Preclinical • Diabetes • Immunology • Macular Degeneration • Thyroid Eye Disease

KRIYA-825 (AAV2.CR2-CR1) for Geographic Atrophy: Characterization of Biological Activity and Biodistribution (ASGCT 2025) - "These findings support further clinical development of KRIYA-825 as a potential one-time sustained therapy for GA. Disease Focus of Abstract:Ophthalmic Diseases"

Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Gene Therapies • Retinal Disorders

A Novel AAV Gene Therapy Complement Inhibitor: KRIYA-825 Exhibits Dose-Dependent Murine Efficacy and NHP Biodistribution (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Gene therapy • Preclinical • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Ophthalmology

VISION: A Study to Evaluate KRIYA-825 (VV-14295) in Adults with Geographic Atrophy Secondary to Age-related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=62 | Recruiting | Sponsor: Kriya Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

VISION: A Study to Evaluate KRIYA-825 (VV-14295) in Adults with Geographic Atrophy Secondary to Age-related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=62 | Not yet recruiting | Sponsor: Kriya Therapeutics, Inc.

New P1/2 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders